Last updated 3 months ago

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

614 patients around the world
Available in Chile, United States
Merck Sharp & Dohme LLC
8Research sites
614Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro Regional Integrado de Oncologia - CRIO
Recruiting
R. Francisco Calaça, 1300 - Álvaro Weyne, Fortaleza - CE, 60335-480
Hospital Tacchini
Recruiting
R. Dr. José Mário Mônaco, 358 - Centro, Bento Gonçalves - RS, 95700-000, Brazil
Instituto de Oncologia Saint Gallen
Recruiting
R. Mal. Deodoro, 1139 - Bonfim, Santa Cruz do Sul - RS, 96810-102, Brazil
Hospital de Câncer de Barretos - Fundação PIO XII
Recruiting
Rua Antenor Duarte Villela 1331 - Barretos, Sao Paulo, 14784-400
AC Camargo Cancer Center
Recruiting
São Paulo, 01509-001
Hospital de Clínicas de Passo Fundo
Recruiting
R. Uruguai, 590 - Centro, Passo Fundo - RS, 99010-110, Brazil
Oncovida - Santiago
Recruiting
Gral. Holley 2381, Providencia, Región Metropolitana, Santiago
Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Recruiting
Portugal 61, Santiago
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy